Endocrine Treatment for Breast Cancer Patients Revisited-History, Standard of Care, and Possibilities of Improvement.
Reads0
Chats0
TLDR
A review of the history of endocrine treatment for breast cancer is presented in this article, where the authors give an overview of the role in the present standard of care, and discuss the possibilities of improvement.Abstract:
Purpose of review: Due to the findings of current studies and the approval of novel substances for the therapy of hormone-receptor-positive breast cancer patients, the established standards of endocrine treatment are changing. The purpose of this review is to give an overview of the history of endocrine treatment, to clarify its role in the present standard of care, and to discuss the possibilities of improvement. Recent findings: Tamoxifen, aromatase inhibitors, and fulvestrant are the main drugs that have been used for decades in the therapy of hormone-receptor-positive breast cancer patients. However, since a relevant number of women suffer at some point from disease recurrence or progression, several novel substances are being investigated to overcome resistance mechanisms by interfering with certain signaling pathways, such as the PI3K/AKT/mTOR or the CDK4/6 pathways. mTOR and CDK4/6 inhibitors were the first drugs approved for this purpose and many more are in development. Summary: Endocrine treatment is one of the best tolerable cancer therapies available. Continuous investigation serves to improve patients’ outcomes and modernize the current standard of care. Considering the resistance mechanisms and substances analyzed against these, endocrine treatment of hormone-receptor-positive breast cancer is on the brink of a new era.read more
Citations
More filters
Journal ArticleDOI
G Protein-Coupled Estrogen Receptor GPER: Molecular Pharmacology and Therapeutic Applications.
TL;DR: The 7-transmembrane G protein-coupled estrogen receptor (GPER) as mentioned in this paper has been shown to activate a diverse array of signaling pathways, including ligand-activated transcription factors.
Journal ArticleDOI
Update on prognostic and predictive biomarkers of breast cancer.
Yanjun Hou,Yan Peng,Zaibo Li +2 more
TL;DR: Several main prognostic and predictive biomarkers in breast cancer at genomic, transcriptomic and proteomic levels are summarized, including hormone receptors, HER2, Ki67, multiple gene expression assays, PD-L1 testing, mismatch repair deficiency/microsatellite instability, tumor mutational burden, PIK3CA, ESR1 andNTRK and the roles of digital imaging analysis in breast biomarker evaluation are introduced.
Journal ArticleDOI
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
Ana Laura López González,Sonia Del Barco Berron,Isabel Grau,María Galán,Beatriz Castelo Fernández,A Cortés,P. Sanchez Rovira,Alejandro Martinez-Bueno,Xavier Gonzalez,Almudena Garcia,Petra Gener,Leonardo Bruno Mina,Daniel Alcala-Lopez,Miguel Sampayo,Javier Cortes,Jose Perez-Garcia,Antonio Llombart-Cussac,Elena López-Miranda +17 more
TL;DR: The results of REVERT clinical study that aimed to reverse the resistance to hormonal treatment that often occurs in breast cancer patients positive for hormone receptors were published in 2019 as mentioned in this paper , where the authors explored whether eribulin could restore endocrine sensitivity in a randomized, non-comparative phase II trial.
Journal ArticleDOI
Targeting Breast Cancer: An Overlook on Current Strategies
Domenico Iacopetta,Jessica Ceramella,Noemi Baldino,Maria Stefania Sinicropi,Alessia Catalano +4 more
TL;DR: An overview of studies in this field is given in this article , presenting the data from the literature concerning the classification of breast cancer and the drugs used in therapy for the treatment of BCs, along with drugs in clinical studies.
Journal ArticleDOI
SERD-NHC-Au(I) complexes for dual targeting ER and TrxR to induce ICD in breast cancer.
Yunlong Lu,Xinyu Sheng,Chao Liu,Zhenlin Liang,Xin Wang,Lijuan Liu,Zhenfan Wen,Zhibin Yang,Qianming Du,Wukun Liu +9 more
TL;DR: In this paper , a selective estrogen receptor degraders (SERDs) candidate was combined with a trioredoxin reductase inhibitor to form dual targeting complexes that can regulate both signaling pathways, which exhibited significant antiproliferative profile through degrading ER and inhibiting TrxR activity.
References
More filters
Journal ArticleDOI
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon,Brian Leyland-Jones,Steven Shak,Hank Fuchs,Virginia E. Paton,Alex Bajamonde,Thomas Fleming,Wolfgang Eiermann,Janet M. Wolter,Mark D. Pegram,José Baselga,Larry Norton +11 more
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Journal ArticleDOI
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond,Daniel F. Hayes,Mitch Dowsett,D. Craig Allred,Karen L. Hagerty,Sunil V. Badve,Patrick L. Fitzgibbons,Glenn Francis,Neil S. Goldstein,Malcolm Hayes,David G. Hicks,Susan C. Lester,Richard Love,Pamela B. Mangu,Lisa M. McShane,Keith Miller,C. Kent Osborne,Soonmyung Paik,Jane Perlmutter,Anthony Rhodes,Hironobu Sasano,Jared N. Schwartz,Fred C.G.J. Sweep,Sheila E. Taube,Emina Torlakovic,Paul N. Valenstein,Giuseppe Viale,Daniel W. Visscher,Thomas M. Wheeler,R. Bruce Williams,James L. Wittliff,Antonio C. Wolff +31 more
TL;DR: An international Expert Panel that conducted a systematic review and evaluation of the literature and developed recommendations for optimal IHC ER/PgR testing performance recommended that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences.
Journal ArticleDOI
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
C Davies,Jon Godwin,Richard Gray,Mike Clarke,D Cutter,Sarah C. Darby,Paul McGale,Huade Pan,C Taylor,Yiwei Wang,Mitch Dowsett,James N. Ingle,Richard Peto +12 more
TL;DR: The absolute risk reductions produced by tamoxifen depend on the absolute breast cancer risks (after any chemotherapy) without tamox ifen, so all-cause mortality was substantially reduced.
Journal ArticleDOI
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark E. Robson,Seock-Ah Im,Elżbieta Senkus,Binghe Xu,Susan M. Domchek,Norikazu Masuda,Suzette Delaloge,Wei Li,Nadine Tung,Anne Armstrong,Wenting Wu,C. Goessl,Sarah Runswick,Pierfranco Conte +13 more
TL;DR: Among patients with HER2‐negative metastatic breast cancer and a germline BRCA mutation, Olaparib monotherapy provided a significant benefit over standard therapy; median progression‐free survival was 2.8 months longer and the risk of disease progression or death was 42% lower with olaparIB monotherapy than with standard therapy.
Journal ArticleDOI
Medication Compliance and Persistence: Terminology and Definitions
Joyce A. Cramer,Anuja Roy,Anita Burrell,Carol J. Fairchild,Mahesh J. Fuldeore,Daniel A. Ollendorf,Peter K. Wong +6 more
TL;DR: Providing specific definitions for compliance and persistence is important for sound quantitative expressions of patients' drug dosing histories and their explanatory power for clinical and economic events and adoption by health outcomes researchers will provide a consistent framework and lexicon for research.
Related Papers (5)
CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives.
Michela Roberto,Antonio Astone,A. Botticelli,Luisa Carbognin,Alessandra Cassano,G. D'Auria,A. Fabbri,Alessandra Fabi,Teresa Gamucci,Eriseld Krasniqi,Mauro Minelli,Armando Orlandi,Francesco Pantano,Ida Paris,Laura Pizzuti,Ilaria Portarena,Nello Salesi,Simone Scagnoli,Paola Scavina,Giuseppe Tonini,Patrizia Vici,Paolo Marchetti,Paolo Marchetti +22 more